The trend of decreasing breast cancer proliferation in the diabetes patient group suggests that indirect insulin- and glucose-mediated effects are the main mechanism of anticancer effect of metformin in human breast cancer and attenuate the role of direct effects on specific pathways concerned on the AMPK/mTOR cascade activity [126]. This evidence concerns the gene MTOR and diabetes mellitus.